



May 12, 2025

WASHINGTON, DC – The Alliance for Longevity Initiatives (A4LI) today announced that Governor Greg Gianforte has signed Montana Senate Bill 535 into law, making Montana the first state to license and oversee experimental treatment centers. The legislation passed both chambers of the Montana Legislature with bipartisan support and establishes a clear licensing and oversight framework for these centers statewide.

Building on Montana’s 2023 Right to Try expansion (SB 422), SB 535 establishes licensing, provider eligibility, safety and reporting requirements, and quality-assurance measures for experimental treatment centers—ensuring rigorous oversight of investigational therapies and transparency for patients.

“The passage of SB 535 is a landmark step toward increasing innovation timelines and patient access to longevity medicine,” said Dylan V. Livingston, Founder and CEO of A4LI. “Today, Montana has set a new standard for legislation that fuels forward-thinking biotech and therapeutic innovation.”

Introduced by State Senator Kenneth Bogner and driven by A4LI alongside its coalition partners, SB 535 underscores bipartisan recognition of the need to accelerate medical innovation and expand access to cutting-edge treatments for all patients. Additionally, data from Montana’s framework can bolster IND submissions and support requests for expedited FDA review for biotechnology companies, potentially speeding development timelines.

A4LI commends Senator Bogner and Representative Buttrey—who carried the bill in the Senate and House, respectively—as well as Governor Gianforte for championing this transformative legislation. The successful enactment of SB 535 serves as a powerful example for other states considering similar reforms and represents a critical step toward making longevity medicine accessible nationwide.

About the Alliance for Longevity Initiatives (A4LI)

The Alliance for Longevity Initiatives (A4LI) is a 501(c)(4) nonprofit advancing policies to extend healthy human lifespan. A4LI unites scientists, policymakers, and industry leaders to drive innovation in longevity biotech and ensure equitable access to next-generation therapies.

Media Inquiries

For more information or for media requests, please reach out to our support team at info@a4li.org.